SAA reverses paclitaxel resistance in human breast cancer bytargeting the expression of transgelin2 and attenuating the PI3K/Akt pathway [34], inactivates transgelin2 [35], protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity [36] and inhibits the growth of A549 lung cancer cells [37]. The gene discussed is AKT1; the disease is breast carcinoma.